AMINOSYN 5% SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

L-ISOLEUCINE; L-LEUCINE; L-LYSINE (L-LYSINE ACETATE); METHIONINE; L-PHENYLALANINE; L-THREONINE; TRYPTOPHAN; L-VALINE; L-TYROSINE; L-ALANINE; L-ARGININE; GLYCINE; L-PROLINE; SERINE; HISTIDINE

Inapatikana kutoka:

HOSPIRA HEALTHCARE ULC

ATC kanuni:

B05BA01

INN (Jina la Kimataifa):

AMINO ACIDS

Kipimo:

360MG; 470MG; 360MG; 200MG; 220MG; 260MG; 80MG; 400MG; 44MG; 640MG; 490MG; 640MG; 430MG; 210MG; 150MG

Dawa fomu:

SOLUTION

Tungo:

L-ISOLEUCINE 360MG; L-LEUCINE 470MG; L-LYSINE (L-LYSINE ACETATE) 360MG; METHIONINE 200MG; L-PHENYLALANINE 220MG; L-THREONINE 260MG; TRYPTOPHAN 80MG; L-VALINE 400MG; L-TYROSINE 44MG; L-ALANINE 640MG; L-ARGININE 490MG; GLYCINE 640MG; L-PROLINE 430MG; SERINE 210MG; HISTIDINE 150MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

250ML/700ML/800ML/1000ML

Dawa ya aina:

Ethical

Eneo la matibabu:

CALORIC AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 1550865004; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2016-07-29

Tabia za bidhaa

PRESCRIBING INFORMATION
AMINOSYN7 5%
AMINOSYN7 7%
AMINOSYN7 8.5%
AMINOSYN7 10%
AMINOSYN
TM/MD RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
SULFITE-FREE
NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION
Hospira Healthcare Corporation
Date of Revision: April 11, 2012
1111 Dr. Frederik-Philips, 6
th
floor
St-Laurent,Quebec
H4M 2X6
CONTROL NOS. 150040 AND 150041
_PRESCRIBING INFORMATION; Aminosyn® 5%, 7%, 8.5%, 10% and RF
Injection 5.2% _
_Page 2 of 14 _
NAMES OF DRUGS:
AMINOSYN
7
5%
AMINOSYN
7
7%
AMINOSYN
7
8.5%
AMINOSYN
7
10%
AMINOSYN
TM/MD
RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
Sulfite-Free
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Nutritive Supplement for Intravenous Infusion
ACTION
1.
PROTEIN SPARING (PERIPHERAL USE)
:
It has been shown that it may be preferable for short periods of time,
3 to 5 days, to mobilize fat (as
in total starvation) for meeting energy requirements to spare protein.
Under conditions of total fasting, lipid mobilization provides energy
substrate in the form of free fatty
acids and ketone bodies. Lipolysis occurs because insulin levels are
low. If high concentrations of
carbohydrates are administered, insulin levels will rise and inhibit
lipid mobilization. With brief
periods of fasting (less than 24 hours), energy requirements are
usually met by glycogenolysis of the
glycogen stored in the liver. However, after glycogen is depleted,
lipolysis of body fat becomes the
fat source of energy.
Thus, when amino acids (without dextrose) are infused into a
peripheral vein, lipolysis and
ketogenesis occur freely and caloric requirements are met without
proteolysis. This spares protein
and the body's muscle mass, while providing a substrate for essential
protein synthesis.
Amino acid peripheral intravenous infusions result in: (1)
availability of free fatty acids and ketone
bodies as sources of energy, and (2) the concomitant utilization of
administered amino acids for
protein synthesis.
2.
ADJUNCTIVE FOR TO